Delusions associated with elevated muscarinic binding in dementia with Lewy bodies
โ Scribed by Clive Ballard; Margaret Piggott; Mary Johnson; Nigel Cairns; Robert Perry; Ian McKeith; Evelyn Jaros; J. O'Brien; Clive Holmes; Elaine Perry
- Publisher
- John Wiley and Sons
- Year
- 2000
- Tongue
- English
- Weight
- 182 KB
- Volume
- 48
- Category
- Article
- ISSN
- 0364-5134
No coin nor oath required. For personal study only.
โฆ Synopsis
The relation between disturbances of cholinergic neurotransmission and delusions (DELs) has not been investigated in degenerative dementias such as dementia with Lewy bodies (DLB). A cohort of dementia patients were assessed with standardized clinical evaluations (including the Columbia University Scale for Psychopathology in Alzheimer's Disease), which were repeated annually until death. DLB was confirmed neuropathologically in 21 patients. Neurochemical evaluation included M1 receptor autoradiography (pirenzepine binding), biochemical measurement of choline acetyltransferase (ChAT), and acetylcholinesterase (AChE) histochemistry in brain regions hypothesized to be involved in the genesis of psychosis. Compared with 11 age-matched controls, ChAT and pirenzepine levels were most extensively reduced in the temporal and parietal neocortex of DLB patients. In Brodmann area 36, DELs were significantly associated with elevated pirenzepine binding (131.0 vs 93.5, t โซุโฌ 2.7), whereas visual hallucinations were associated with significant reductions in ChAT (1.7 vs 2.5, t โซุโฌ 2.5). There were no significant associations with other areas or with cholinesterase. Although DELs and visual hallucinations were both linked with disturbances in cholinergic neurotransmission, the nature of the associations was different. Upregulation of the postsynaptic muscarinic receptor may be central in the genesis of DELs, with important treatment implications.
๐ SIMILAR VOLUMES
Objectives. Dementia with Lewy bodies (DLB) is now a well-recognized form of dementia in which psychosis and behavioural disturbance are common. Treatment with conventional neuroleptics is often very poorly tolerated. Olanzapine, a newly introduced atypical neuroleptic which binds to multiple recept